Stock Track | Sino Biopharmaceutical Soars 5.00% Intraday on AstraZeneca and GSK Partnerships and NDA Milestone

Stock Track07-10

Sino Biopharmaceutical's stock price soared 5.00% during intraday trading on Friday, following significant positive developments from the company.

The surge comes after the company announced that its subsidiary Beijing Tide had a New Drug Application (NDA) for a world-first long-acting ropivacaine hydrochloride sustained-release solution for postoperative analgesia accepted by China's Center for Drug Evaluation. Additionally, another subsidiary granted AstraZeneca exclusive ex-China rights to the inhaled respiratory drug TQC3721, which includes a substantial US$200 million upfront payment and potential future milestones worth up to US$1.9 billion.

Simultaneously, Sino Biopharmaceutical expanded its exclusive strategic partnership with GSK, securing commercialization rights for two blockbuster COPD drugs in mainland China. These consecutive global licensing deals have been viewed by analysts as strong validation of the company's internal R&D innovation capabilities, with Goldman Sachs raising earnings estimates and CMB International maintaining a Buy rating on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119759938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119759938","market":"sg","top_or_hot":-1,"title":"Stock Track | Sino Biopharmaceutical Soars 5.00% Intraday on AstraZeneca and GSK Partnerships and NDA Milestone","media":"Stock Track","content":"<p>Sino Biopharmaceutical's stock price soared 5.00% during intraday trading on Friday, following significant positive developments from the company.</p><p>The surge comes after the company announced that its subsidiary Beijing Tide had a New Drug Application (NDA) for a world-first long-acting ropivacaine hydrochloride sustained-release solution for postoperative analgesia accepted by China's Center for Drug Evaluation. Additionally, another subsidiary granted AstraZeneca exclusive ex-China rights to the inhaled respiratory drug TQC3721, which includes a substantial US$200 million upfront payment and potential future milestones worth up to US$1.9 billion.</p><p>Simultaneously, Sino Biopharmaceutical expanded its exclusive strategic partnership with GSK, securing commercialization rights for two blockbuster COPD drugs in mainland China. These consecutive global licensing deals have been viewed by analysts as strong validation of the company's internal R&D innovation capabilities, with Goldman Sachs raising earnings estimates and CMB International maintaining a Buy rating on the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sino Biopharmaceutical Soars 5.00% Intraday on AstraZeneca and GSK Partnerships and NDA Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sino Biopharmaceutical Soars 5.00% Intraday on AstraZeneca and GSK Partnerships and NDA Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-10 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sino Biopharmaceutical's stock price soared 5.00% during intraday trading on Friday, following significant positive developments from the company.</p><p>The surge comes after the company announced that its subsidiary Beijing Tide had a New Drug Application (NDA) for a world-first long-acting ropivacaine hydrochloride sustained-release solution for postoperative analgesia accepted by China's Center for Drug Evaluation. Additionally, another subsidiary granted AstraZeneca exclusive ex-China rights to the inhaled respiratory drug TQC3721, which includes a substantial US$200 million upfront payment and potential future milestones worth up to US$1.9 billion.</p><p>Simultaneously, Sino Biopharmaceutical expanded its exclusive strategic partnership with GSK, securing commercialization rights for two blockbuster COPD drugs in mainland China. These consecutive global licensing deals have been viewed by analysts as strong validation of the company's internal R&D innovation capabilities, with Goldman Sachs raising earnings estimates and CMB International maintaining a Buy rating on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1119759938","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119759938","pubTimestamp":1783650915,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Sino Biopharmaceutical's stock price soared 5.00% during intraday trading on Friday, following significant positive developments from the company.The surge comes after the company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"股票追踪 | 阿斯利康和葛兰素史克的合作以及 NDA 里程碑，中国生物制药盘中飙升 5.00%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"Sino Biopharmaceutical's stock price soared 5.00% during intraday trading on Friday, following significant positive developments from the company.The surge comes after the company announced that its subsidiary Beijing Tide had a New Drug Application (NDA) for a world-first long-acting ropivacaine hydrochloride sustained-release solution for postoperative analgesia accepted by China's Center for Drug Evaluation. Additionally, another subsidiary granted AstraZeneca exclusive ex-China rights to the inhaled respiratory drug TQC3721, which includes a substantial US$200 million upfront payment and potential future milestones worth up to US$1.9 billion.Simultaneously, Sino Biopharmaceutical expanded its exclusive strategic partnership with GSK, securing commercialization rights for two blockbuster COPD drugs in mainland China. These consecutive global licensing deals have been viewed by analysts as strong validation of the company's internal R&D innovation capabilities, with Goldman Sachs raising earnings estimates and CMB International maintaining a Buy rating on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119759938","isCrawlerRequest":true}